SBIR-STTR Award

The Development Of Cross-Platform Quantitative Standards For Diagnostic Immunohis
Award last edited on: 1/30/09

Sponsored Program
STTR
Awarding Agency
NIH : NCI
Total Award Amount
$100,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Robert L Camp

Company Information

HistoRx Inc

35 Northeast Industrial Road
Branford, CT 06405
   (203) 498-7500
   info@historx.com
   www.historx.com

Research Institution

----------

Phase I

Contract Number: 1R41CA134335-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2008
Phase I Amount
$100,000
Patient-specific therapies targeted to the phenotype of individual tumors represent the future of cancer treatment. The prototypes for this type of therapy are Herceptin and Tamoxifen, which are only given to patients expressing a particular level of HER2 and estrogen receptor (ER), respectively. It is likely that dozens of such therapies will be developed for a variety of tumors in the next decade. As with Herceptin and Tamoxifen, the diagnostic test for determining which patients will be given what therapies will most likely involve immunohistochemical (IHC) staining of fixed tumor samples, since the routine H&E slide remains the standard for the anatomic diagnosis. Yet today's immunohistology labs have only the crudest of standards-usually a highly positive and a completely negative cell line or tissue control. The results from such stains are likely only accurate to at best one order of magnitude, even when newer automated quantitative stain readers are used. Furthermore, no attempt is made to assess the antigenic viability of patient samples. We believe that the future success of targeted therapy will be largely dependent upon the development of robust method of standardization for IHC that can be used to normalize results both across laboratories and across analysis platforms. Our goal is to develop a robust, adaptable immunohistochemical standard that can be processed alongside every patient tissue sample. This standard can then be used both to assess tissue antigenic viability and to permit the quantification of biomarkers at the molecules-per-cell level.

Public Health Relevance Statement:
Patient-specific therapies represent the future of cancer treatment. Development of such therapies will require consistent and quantitative measures of patient tumors. Our goal is to develop robust, adaptable, and quantitative standards that can dramatically improve the analysis of patient tumors. These standards will help determine the most appropriate therapy for a patient's tumor.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----